Etanercept biosimilar (AryoGen Biopharma)

依那西普生物类似药 (AryoGen Biopharma)

Report date: 2022/01/14 13:23:58

Base Information

Drug NameEtanercept biosimilar (AryoGen Biopharma)
Drug Alias Name依那西普生物仿制药 (AryoGen Biopharma)Altebrel
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein > Fc fusion proteinBiologics > Biosimilar
Mechanisms of ActionTumor necrosis factor β inhibitorsTumor necrosis factor α inhibitors
TargetsTumor necrosis factor βTumor necrosis factor α
Therapy Area/IndicationsPsoriasisArthritis, RheumatoidArthritis, Juvenile +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesAryogen Biopharma
China Registration ClassN/A

Develop Information

Active CompaniesAryogen Biopharma
Inactive CompaniesN/A
Active IndicationsPsoriasisArthritis, RheumatoidArthritis, Juvenile +[5] 
Inactive IndicationsN/A

Other Information

ATC CodeL04AB01
Related LinksN/A